Last reviewed · How we verify
Niagen
At a glance
| Generic name | Niagen |
|---|---|
| Also known as | Nicotinamide Riboside, 3-(Aminocarbonyl)-1-β-D-ribofuranosyl-pyridinium chloride, TruNiagen, Vitamin B3, nicotinamide riboside chloride |
| Sponsor | University of Maryland, Baltimore |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia (EARLY_PHASE1)
- Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus (PHASE1, PHASE2)
- Nicotinamide Riboside in Ulcerative Colitis (NA)
- Nicotinamide Riboside for Diabetic Neuropathy (PHASE1, PHASE2)
- N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease (PHASE2)
- Randomized, Open-label, Safety Study of Subcutaneous and Intramuscular Injections of Niagen® Plus (PHASE1)
- The Effect of Exercise and Nicotinamide Riboside Muscle Health and Insulin Resistance in Survivors of Childhood Cancer (NA)
- Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Niagen CI brief — competitive landscape report
- Niagen updates RSS · CI watch RSS
- University of Maryland, Baltimore portfolio CI